/
Other
Coagulation
3
Pipeline Programs↗
4
Active Trials↗
10
Companies Involved↗
Coagulation is an early-stage landscape with 3 programs across 10 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Phase 31
Approved
No programs
Analysis
Modality Breakdown
67%
Monoclonal antibody
2 of 3 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
41
clinical trials
Completed24 · 59%
Unknown status10 · 24%
Terminated3 · 7%
Recruiting2 · 5%
Not yet recruiting1 · 2%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
41 trials
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Completed·—·Phase 2·NCT05265286·15 enrolled
Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
Completed·—·N/A·NCT01536496·114 enrolled
Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
Completed·—·N/A·NCT03054766·80 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)